News & Events

Redbiotec is pleased to announce that it has further validated its complex CMV antigens in two new in vivo (mouse) studies. One performed in house, one by a pharma partner. Redbiotec’s complex CMV antigens showed high neutralizing antibody titers even at low dose, both as standalone product as well as in a formulation combined with another CMV glycoprotein. For further information please do not hesitate to contact schaub@redbiotec.ch.

Redbiotec and the research group of Prof. William J. Britt, MD announce a collaboration to study the contribution of complex antigens to protective immunity against Cytomegalovirus (CMV). The goal of the study is to gain insights into the correlates of protection.

Redbiotec will provide proprietary CMV antigens to be tested in sera from a target patient population, an important milestone towards validation of Redbiotec’s CMV vaccine candidates. The study is a continuation of an ongoing collaboration with Prof. Britt.

Redbiotec is pleased to announce the publication of the patent applicaton (WO2014/068001) for which the previously issued preliminary search report was very positive.

Redbiotec announces today the appointment of Prof. Monique van Oers from Wageningen University to Redbiotec’s team. Professor van Oers is a leading baculovirus expert and inventor of a virion-free baculovirus expression system.

Redbiotec CEO Christian Schaub has been invited to an exclusive special event at the Swiss Economic Forum 2014 in Interlaken. Christian will be participant of a panel discussion on the Growth Initiative chaired by Peter Stähli, CEO of the Swiss Economic Forum.